Recommended Dosing for Bevacizumab, Gemcitabine, and Carboplatin in Ovarian Cancer
For platinum-sensitive recurrent ovarian cancer, administer gemcitabine 1000 mg/m² IV over 30 minutes on Days 1 and 8, carboplatin AUC 4 IV on Day 1 after gemcitabine, and bevacizumab 10 mg/kg or 15 mg/kg IV on Day 1, repeated every 21 days. 1
FDA-Approved Dosing Regimen
The FDA label provides the definitive dosing for gemcitabine-carboplatin in ovarian cancer 1:
- Gemcitabine: 1000 mg/m² IV over 30 minutes on Days 1 and 8 of each 21-day cycle
- Carboplatin: AUC 4 IV on Day 1 after gemcitabine administration
- Bevacizumab: While the NCCN guidelines indicate bevacizumab is FDA-approved for use with carboplatin and gemcitabine in platinum-sensitive recurrent disease 2, the standard dosing is 10-15 mg/kg IV every 3 weeks
Clinical Context and Evidence
Platinum-Sensitive Recurrent Disease
The gemcitabine-carboplatin-bevacizumab triplet is specifically indicated for platinum-sensitive recurrent ovarian cancer (relapse ≥6 months after platinum-based therapy) 2, 1. The NCCN guidelines explicitly list this combination as an FDA-approved regimen, with bevacizumab continued as maintenance after chemotherapy completion 2.
Alternative Dosing Schedules
Research studies have explored modified dosing schedules:
- Biweekly regimen: Gemcitabine 1000 mg/m², carboplatin AUC 3, and bevacizumab 10 mg/kg on Days 1 and 15 of a 28-day cycle showed a median PFS of 13.3 months with 69% response rate 3
- Day 1/Day 15 schedule: Using cisplatin 30 mg/m² instead of carboplatin demonstrated 78% response rate but with higher toxicity 4
However, prioritize the FDA-approved 21-day cycle regimen 1 as it represents the standard of care with established safety data.
Dose Modifications for Toxicity
Critical dose adjustments based on myelosuppression 1:
On Day 8 of treatment:
- ANC ≥1500 × 10⁶/L AND platelets ≥100,000 × 10⁶/L: Full dose
- ANC 1000-1499 × 10⁶/L OR platelets 75,000-99,999 × 10⁶/L: 50% dose reduction
- ANC <1000 × 10⁶/L OR platelets <75,000 × 10⁶/L: Hold dose
For severe toxicity in previous cycle:
- Initial occurrence of ANC <500 × 10⁶/L for >5 days, ANC <100 × 10⁶/L for >3 days, febrile neutropenia, or platelets <25,000 × 10⁶/L: Reduce gemcitabine to 800 mg/m² on Days 1 and 8
- Subsequent occurrence: Further reduce to 800 mg/m² on Day 1 only
Bevacizumab Dosing Considerations
Recent evidence suggests bevacizumab 7.5 mg/kg may be equivalent to 15 mg/kg in terms of overall survival while reducing financial toxicity 5. However, the standard FDA-approved dose remains 10-15 mg/kg every 3 weeks 2. The 10 mg/kg dose is most commonly used in clinical trials 3, 4, 6, 7.
Important Caveats
- Bevacizumab continuation: After completing 6 cycles of chemotherapy, continue bevacizumab as single-agent maintenance 2
- Platinum-resistant disease: This triplet regimen may be considered for platinum-resistant ovarian cancer with PFI 3-6 months, showing median PFS of 7.9 months 6, though single-agent therapies are typically preferred 8
- Hematologic toxicity: Expect grade 3-4 neutropenia in 27-71% and thrombocytopenia in 2-26% of patients 3, 6. Growth factor support may be necessary
- Bowel perforation risk: Monitor for this serious bevacizumab-related complication, occurring in approximately 2-6% of patients 3, 4